CHRS News and Press, Coherus BioSciences Inc. From 03/13/24

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...

2024-03-12 17:35:31 ET Major earnings expected after the bell on Wednesday include: UiPath ( PATH ) SentinelOne ( S ) Lennar Corporation ( LEN ) GrowGeneration Corp. ( GRWG ) Limbach Holdings ( LMB ) Read the full article on Seeking Alpha ...

2024-03-12 17:35:19 ET More on Coherus BioSciences Coherus BioSciences: FDA Approvals Spice Up The Pipeline Biggest stock movers today: Boeing, NuStar Energy, Archer-Daniels-Midland, and more Sandoz to acquire Cimerli business from Coherus BioSciences for $170M in al...

REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on ...

Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...

– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ: CHRS) today announce...

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDENYCA ® – REDWOOD CITY, Calif.,...

2024-02-12 04:47:00 ET Summary For the week just past, the S&P 500 was up 1.4%. Even though Magnificent 7 stocks continue to lead the market higher, market participation is broadening out, which is a healthy sign. The ProShares Bitcoin Strategy ETF took the top spot on the...

- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be reduced by ~70% - REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, ...

2024-01-23 11:37:14 ET Shares of Coherus BioSciences (NASDAQ: CHRS) were sinking 8.6% lower as of 11:14 a.m. ET on Tuesday. The decline followed a nice pop for the stock on Monday after Coherus announced it was selling its Cimerli ophthalmology franchise to Sandoz Group . Th...